The Electronic Asthma Management System (eAMS) Improves Primary Care Asthma Management

Samir GuptaCourtney PriceGina AgarwalDavid ChanSanjeev GoelLouis-Philippe BouletAlan G. KaplanGerald LebovicMuhammad MamdaniSharon E. Straus
 

Abstract

A high prevalence of suboptimal asthma control is attributable to known evidence-practice gaps. We developed a computerised clinical decision support system (the Electronic Asthma Management System – eAMS) to address major care gaps and sought to measure its impact on care in adults with asthma.

This was a 2-year interrupted time series study of usual care (year 1) versus eAMS (year 2) at 3 Canadian primary care sites. We included asthma patients aged ≥16 years receiving an asthma medication within the last 12 months. The eAMS consisted of a touch tablet patient questionnaire completed in the waiting room, with real-time data processing producing electronic medical record-integrated clinician decision support.

Action plan delivery (primary outcome) improved from 0/412 (0%) to 79/443 (17.8%) eligible patients [absolute increase 0.18 (0.14,0.22)]. Time series analysis indicated a 30.5% increase in physician visits with action plan delivery with the intervention (p<0.0001). Assessment of asthma control level increased from 173/3497 (4.9%) to 849/3062 (27.7%) eligible visits [adjusted OR 8.62 (5.14, 12.45)]. Clinicians escalated controller therapy in 108/3422 (3.2%) baseline visits versus126/3240 (3.9%) intervention visits (p=0.12). At baseline, a short-acting beta-agonist alone was added in 62 visits and a controller added in 54 visits; with the intervention, this occurred in 33 and 229 visits, respectively (p<0.001).

The eAMS improved asthma quality of care in real-world primary care settings. Strategies to further increase clinician uptake and a randomised controlled trial to assess impact on patient outcomes are now required.

Registration: ClinicalTrials.govNCT01070095

 PDF

 
 

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: FDA to Review BLA for Oral Immunotherapy AR101 for Peanut Allergy - Pulmonology Advisor… https://t.co/JSl0Dhdy2k
3hreplyretweetfavorite
Interasma RT @Aller_MD: “VIDEO: #Dupilumab or cyclosporine for treating atopic dermatitis?” https://t.co/sIseou6JYq https://t.co/4h02wi3UUa
7hreplyretweetfavorite
Interasma RT @Aller_MD: “More than one in five infants with a bronchiolitis hospital admission will have a subsequent respiratory-related hospital ad…
7hreplyretweetfavorite
Interasma RT @Aller_MD: “FDA to Review BLA for Oral Immunotherapy AR101 for Peanut #Allergyhttps://t.co/4UDldOOtRd https://t.co/HNeJTDeR9s
7hreplyretweetfavorite
Interasma RT @Aller_MD: 10 startups tackling the problem of high prescription drug costs. Managing payments, connecting consumers to reimbursement op…
7hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma